Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: Early effects on mood, performance, and vital signs

Journal of Clinical Psychopharmacology

Volumn 26, Issue 5, 2006, Pages 519-523

  Uhlenhuth, E H ^a   Starcevic, Vladan ^b   Qualls, Clifford ^a   Antal, Edward J ^c   Matuzas, William ^d   Javaid, Javaid I ^e   Barnhill, Jamie ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Jasper Clinic   (United States)

^d Maine General Medical Center   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPHORIA; EMOTION; FATIGUE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MALE; MATHEMATICAL ANALYSIS; MEASUREMENT; MOOD; PANIC; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TASK PERFORMANCE; THINKING; TREATMENT DURATION; VITAL SIGN; WEAKNESS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AFFECT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; BLOOD PRESSURE; COGNITION; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33748748538     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000236653.85791.60     Document Type: Article

References (26)

1. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 2003;160:1432-1438.
2. Covi L, Lipman RS, Pattison JH, et al. Length of treatment with anxiolytic sedatives and response to their sudden withdrawal. Acta Psychiatr Scand. 1973;49:51-64.
3. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998;98(suppl 393):95-101.
4. Petursson H, Lader M. Withdrawal from long-term benzodiazepine treatment. Br Med J. 1981;283:643-645.
5. Tyrer P, Owen R, Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet. 1983;1:1402-1406.
6. Roy-Byrne P, Russo J, Pollack M, et al. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003;33:511-518.
7. Beck AT, Emery G. Anxiety Disorders and Phobias: A Cognitive Perspective. New York, NY: Basic Books; 1985.
8. Uhlenhuth EH, Starcevic V, Warner TD, et al. A general anxiety-prone cognitive style in anxiety disorders. J Affect Disord. 2002;70:241-249.
9. Barlow DH, Gorman JM, Shear MK, et al. A randomized controlled trial of cognitive-behavioral treatment vs. imipramine and their combination for panic disorder: primary outcome results. JAMA. 2000;283:2529-2536.
10. Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry. 1993;150:1485-1490.
11. Bruce TJ, Spiegel DA, Hegel MT. Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol. 1999;67:151-156.
12. Spitzer RL, Williams JBW. Instruction Manual for the Structured Clinical Interview for DSM-III-R, Upjohn Version (SCID-UP, 5/1/1988 revision). New York, NY: Biometric Research Department, New York State Psychiatric Institute; 1988.
13. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413-422.
14. Beck AT. Cognitive Therapy and the Emotional Disorders. New York, NY: International Universities Press; 1976.
15. Ganellen RJ, Matuzas W, Uhlenhuth EH, et al. Panic disorder, agoraphobia, and anxiety-relevant cognitive style. J Affect Disord. 1986;11:219-225.
16. Uhlenhuth EH, McCarty T, Paine S, et al. The revised Anxious Thoughts and Tendencies (AT and T) scale: a general measure of anxiety-prone cognitive style. J Affect Disord. 1999;52:51-58.
17. Khawaja NG, Dyer EJ. Anxious Thoughts and Tendencies Scale: an investigation of factor structure and the psychometric properties on the basis of an Australian sample. J Affect Disord. 2004;79:217-221.
18. Javaid JI, Liskevych U. Quantitative analysis of alprazolam in human plasma by combined capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 1986;13:129-132.
19. McNair D, Lair M, Droppleman LY. Profile of Mood States (Manual). San Diego, CA: Educational and Industrial Testing Service; 1971.
20. Letz R, Baker EL. Neurobehavioral System 2 Users Manual, Version 4.2. Albany, CA: Neurobehavioral Systems, Inc; 1988.
21. SAS Institute, Inc. SAS/STAT User's Guide, Version 8.2. Cary, NC: SAS Institute, Inc; 1999.
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum; 1988.
23. Schweizer E, Rickels K, Case WG, et al. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47:908-915.
24. Hoehn-Saric R, McLeod DR, Zimmerli WD. Psychophysiological response patterns in panic disorder. Acta Psychiatr Scand. 1991;83:4-11.
25. Reiss S, Peterson R, Gursky DM, et al. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24:1-8.
26. Chambless DL, Caputo GC, Bright P, et al. Assessment of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol. 1984;52:1090-1097.